雷泮赛珠单抗
雷泮赛珠单抗（INN：Ralpancizumab[1]；开发代码：RN317、PF‐05335810）是一种人源化单克隆抗体，设计用于治疗血脂异常。该药物的靶点是PCSK9，目前已经进行了I期临床试验。[2][3]这种药物是由辉瑞公司开发的。
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目标 | PCSK9 |
| 临床资料 | |
| 其他名称 | RN317、PF‐05335810 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1407495-04-8 |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6422H9922N1730O2012S54 |
| 摩尔质量 | 145,289.36 g·mol−1 |
参考资料
编辑- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 (PDF). WHO Drug Information. 2013, 27 (4) [2023-12-27]. （原始内容存档 (PDF)于2020-08-15）.
- ^ Ralpancizumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
- ^ Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD. A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy. Clinical and Translational Science. January 2017, 10 (1): 3–11. PMC 5351011
. PMID 27860267. doi:10.1111/cts.12430.
